Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris

NCT00787943 | Completed Results DMC

• 1 other identifier: AP-032408
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a split face, paired-comparison, pilot study of 10 subjects. Participants in this study will be patients seen at Children's Memorial Hospital, who are clinically diagnosed with mild to moderate acne vulgaris. Participants will be recruited from the clinic, as well as advertising and from previous Institutional Review Board (IRB) approved acne studies housed in the Department of Dermatology. All subjects accrued from previous studies have agreed to be contacted for further investigations. Subjects 13 to 35 years of age with mild to moderate acne vulgaris symmetrical in appearance on both sides of the face, and meeting inclusion criteria will be eligible to participate.

Conditions

Acne Vulgaris

Keywords

Acne

Outcome Measures

Primary Outcomes (1)

• Number of Inflammatory Lesions (Papules and Pustules)

  Assessment will be done based on lesion counting. We will compare the lesions treated twice daily with the benzoyl peroxide 10.0% cream Formulation #1 vs. the benzoyl peroxide 10.0% cream Formulation #2.

  4 Weeks

Study Arms (2)

Left side of face

EXPERIMENTAL

Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to left side of the face.

Drug: Topical benzoyl peroxide 10.0% cream - Formulation 1; Drug: Topical benzoyl peroxide 10.0% cream - Formulation 2

Right side of face

EXPERIMENTAL

Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to right side of the face.

Drug: Topical benzoyl peroxide 10.0% cream - Formulation 1; Drug: Topical benzoyl peroxide 10.0% cream - Formulation 2

Interventions

Topical benzoyl peroxide 10.0% cream - Formulation 1 DRUG

Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.

Also known as: Benzoyl Peroxide 10% Cream

Left side of face; Right side of face

Topical benzoyl peroxide 10.0% cream - Formulation 2 DRUG

Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.

Also known as: Benzoyl Peroxide 10% Cream

Left side of face; Right side of face

Eligibility Criteria

• Age: 13 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Healthy male or female subjects who are 13 to 35 years of age.
• Subjects are in good health and are free of any other facial skin disorders that may interfere with acne study assessments.
• Subjects have the willingness and ability to understand and provide informed assent/consent to participate in the study and are able to communicate with the investigator. Subjects are willing and able to follow all study directions and to commit to all follow-up visits for the duration of the study. In addition, subjects must be willing to accept the restrictions of the study.
• A minimum of 5 inflammatory lesions (papules and pustules) on each side of the face, and a minimum of 5 non-inflammatory lesions (open comedones and closed comedones) on each side of the face. Lesions should be relatively symmetrical in appearance on both sides of the face. At least one inflammatory lesion should be measured no smaller than 2 mm in diameter and should be visible on each side of the face in images taken with digital imaging station.
• Ongoing oral medications (other than those specifically for acne) are acceptable provided subjects are on a stable regimen throughout the study and provided the medications are determined likely to not interfere with study assessments.
• Subjects will not use medicated cosmetics and/or soaps (including soaps containing antibacterial agents such as benzoyl peroxide, keratolytic agents such as salicylic acid, skin fresheners/astringents or aftershave lotions) for the duration of the study.
• Subjects who agree not to use any other acne treatment (including prescription and non-prescription medications) on the test site for the duration of the study.
• Subjects who agree not to change facial cosmetic products during the study.
• Subjects who agree to only use sunscreen/sunblock agents that are labeled as non-comedogenic.

You may not qualify if:

• Subjects or parents of subjects who are unable to understand the protocol or to give informed consent/assent.
• Subjects with mental illness.
• Subjects with no inflammatory acne.
• Subjects with any acne cysts or nodules.
• Subjects with acne conglobata, acne fulminans, secondary acne (e.g. Chloracne, drug-induced acne), or any acne requiring systemic treatment.
• Subjects with excessive facial hair that may interfere with study assessments.
• Subjects with other facial skin disorders that may interfere with study assessments.
• Subjects with a history of skin cancer or actinic keratosis.
• Subjects who have used tanning devices within one week prior to baseline study visit.
• Subjects who have applied any topical products (e.g. emollients, sunscreens) or any cosmetics to the face at least one hour prior to study assessments.
• Use of hormonal oral contraceptives for acne control or for less than 6 months prior to study baseline.
• Subjects with known allergies, a history of allergy or sensitivity to benzoyl peroxide, or any of the test article components.
• Subjects using topical or systemic medication within 14 days before the study entry, which could interfere with study assessments. This includes but is not limited to the following: anti-inflammatory drugs (e.g. topical and systemic corticosteroids and systemic antihistamines), anti-acne drugs, topical and oral retinoids, topical antibacterial agents to the face, and any immunosuppressive drugs. Ongoing oral medications not expected to interfere with study assessments are allowed if the subject is on a stable regimen.
• Subjects who are currently enrolled in another clinical investigation or have been enrolled in an acne trial within a period of 30 days prior to enrollment in this study.

Sponsors & Collaborators

• Northwestern University: lead

Study Sites (1)

Ann & Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Benzoyl Peroxide

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

Benzoates; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons

Results Point of Contact

• Title: Amy Paller, MD
• Organization: Northwestern University

apaller@northwestern.edu

312-695-3721

Study Officials

• Amy Paller, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: November 6, 2008
• First Posted: November 10, 2008
• Study Start: May 1, 2008
• Primary Completion: January 1, 2009
• Study Completion: January 1, 2009
• Last Updated: May 1, 2015
• Results First Posted: November 17, 2010

Record last verified: 2015-03

Locations

US (1)